{"transactions":[{"id":725989,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-26T20:53:07.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":4392,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date."}],"balance_after":4392,"derivative":{"underlying":"Common Stock","underlying_shares":4392},"source":{"system":"sec-edgar","filing":"0001410781-26-000008","document":"wk-form4_1782507185.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078126000008/wk-form4_1782507185.xml","form_type":"4"}},{"id":729761,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-23T20:35:45.000Z","date":"2026-06-19","kind":"exercise","planned":false,"acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001410781-26-000006","document":"wk-form4_1782246942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078126000006/wk-form4_1782246942.xml","form_type":"4"}},{"id":729760,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T20:35:45.000Z","date":"2026-06-19","kind":"exercise","planned":false,"acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that vested June 19, 2026."}],"balance_after":14150,"source":{"system":"sec-edgar","filing":"0001410781-26-000006","document":"wk-form4_1782246942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078126000006/wk-form4_1782246942.xml","form_type":"4"}},{"id":747777,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T22:17:57.000Z","date":"2026-06-04","kind":"grant","planned":true,"acquired":true,"shares":32996,"price":6.15,"value":202925.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date."}],"balance_after":32996,"derivative":{"exercise_price":6.15,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":32996},"source":{"system":"sec-edgar","filing":"0001410781-26-000004","document":"wk-form4_1780697874.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000141078126000004/wk-form4_1780697874.xml","form_type":"4"}},{"id":747776,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T22:17:57.000Z","date":"2026-06-04","kind":"grant","planned":true,"acquired":true,"shares":24193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the \"Plan\"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date."}],"balance_after":707276,"source":{"system":"sec-edgar","filing":"0001410781-26-000004","document":"wk-form4_1780697874.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000141078126000004/wk-form4_1780697874.xml","form_type":"4"}},{"id":747775,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T22:17:57.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":6.0948,"value":91422.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":683083,"source":{"system":"sec-edgar","filing":"0001410781-26-000004","document":"wk-form4_1780697874.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000141078126000004/wk-form4_1780697874.xml","form_type":"4"}},{"id":763555,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T22:12:11.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":52666,"source":{"system":"sec-edgar","filing":"0001104659-26-066412","document":"tm2615478-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465926066412/tm2615478-4_4seq1.xml","form_type":"4"}},{"id":787830,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to purchase)","published_at":"2026-05-08T20:07:59.000Z","date":"2026-05-07","kind":"exercise","planned":false,"acquired":false,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares of Axogen, Inc. common stock underlying the board of director stock option were fully vested on June 6, 2025."}],"balance_after":0,"derivative":{"exercise_price":7.04,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001410781-26-000002","document":"wk-form4_1778270876.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078126000002/wk-form4_1778270876.xml","form_type":"4"}},{"id":787829,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-08T20:07:59.000Z","date":"2026-05-07","kind":"sale","planned":false,"acquired":false,"shares":11050,"price":43.255,"value":477967.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.25 to $43.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001410781-26-000002","document":"wk-form4_1778270876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078126000002/wk-form4_1778270876.xml","form_type":"4"}},{"id":787828,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-08T20:07:59.000Z","date":"2026-05-07","kind":"exercise","planned":false,"acquired":true,"shares":11050,"price":7.04,"value":77792.0,"ownership":{"direct":true},"balance_after":11050,"source":{"system":"sec-edgar","filing":"0001410781-26-000002","document":"wk-form4_1778270876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078126000002/wk-form4_1778270876.xml","form_type":"4"}},{"id":961939,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-19T22:17:45.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":135400,"price":7.2158,"value":977019.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.200 to $7.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":698083,"source":{"system":"sec-edgar","filing":"0001410781-25-000006","document":"wk-form4_1766182662.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000141078125000006/wk-form4_1766182662.xml","form_type":"4"}},{"id":975256,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-10T22:19:01.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":false,"shares":8545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":6.3,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":8545},"source":{"system":"sec-edgar","filing":"0001410781-25-000004","document":"wk-form4_1765405138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078125000004/wk-form4_1765405138.xml","form_type":"4"}},{"id":975255,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-10T22:19:01.000Z","date":"2025-12-08","kind":"exercise","planned":false,"acquired":false,"shares":11891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date."}],"balance_after":8545,"derivative":{"exercise_price":6.3,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":11891},"source":{"system":"sec-edgar","filing":"0001410781-25-000004","document":"wk-form4_1765405138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078125000004/wk-form4_1765405138.xml","form_type":"4"}},{"id":975254,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T22:19:01.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":13141,"price":29.982,"value":393993.462,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001410781-25-000004","document":"wk-form4_1765405138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078125000004/wk-form4_1765405138.xml","form_type":"4"}},{"id":975253,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T22:19:01.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":8545,"price":29.982,"value":256196.19,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.98 to $30.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":13141,"source":{"system":"sec-edgar","filing":"0001410781-25-000004","document":"wk-form4_1765405138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078125000004/wk-form4_1765405138.xml","form_type":"4"}},{"id":975252,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T22:19:01.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":true,"shares":8545,"price":6.3,"value":53833.5,"ownership":{"direct":true},"balance_after":21686,"source":{"system":"sec-edgar","filing":"0001410781-25-000004","document":"wk-form4_1765405138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078125000004/wk-form4_1765405138.xml","form_type":"4"}},{"id":975251,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T22:19:01.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":11891,"price":31.223,"value":371272.693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":13141,"source":{"system":"sec-edgar","filing":"0001410781-25-000004","document":"wk-form4_1765405138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078125000004/wk-form4_1765405138.xml","form_type":"4"}},{"id":975250,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T22:19:01.000Z","date":"2025-12-08","kind":"exercise","planned":false,"acquired":true,"shares":11891,"price":6.3,"value":74913.3,"ownership":{"direct":true},"balance_after":25032,"source":{"system":"sec-edgar","filing":"0001410781-25-000004","document":"wk-form4_1765405138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078125000004/wk-form4_1765405138.xml","form_type":"4"}},{"id":975249,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T22:19:01.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":11802,"price":31.26,"value":368930.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":13141,"source":{"system":"sec-edgar","filing":"0001410781-25-000004","document":"wk-form4_1765405138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000141078125000004/wk-form4_1765405138.xml","form_type":"4"}},{"id":1065203,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T20:57:39.000Z","date":"2025-08-13","kind":"sale","planned":false,"acquired":false,"shares":107500,"price":7.3159,"value":786459.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.420, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":833483,"source":{"system":"sec-edgar","filing":"0001867096-25-000141","document":"wk-form4_1755291454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709625000141/wk-form4_1755291454.xml","form_type":"4"}},{"id":1105642,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-20T20:11:10.000Z","date":"2025-06-19","kind":"grant","planned":false,"acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date."}],"balance_after":14150,"derivative":{"underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0000805928-25-000102","document":"wk-form4_1750450260.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000102/wk-form4_1750450260.xml","form_type":"4"}},{"id":1115735,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T20:23:19.000Z","date":"2025-06-09","kind":"sale","planned":false,"acquired":false,"shares":4073,"price":10.61,"value":43214.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025, in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units."}],"balance_after":24943,"source":{"system":"sec-edgar","filing":"0000805928-25-000081","document":"wk-form4_1749673393.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000081/wk-form4_1749673393.xml","form_type":"4"}},{"id":1122695,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T23:01:31.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders."}],"balance_after":940983,"source":{"system":"sec-edgar","filing":"0001867096-25-000108","document":"wk-form4_1749078084.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709625000108/wk-form4_1749078084.xml","form_type":"4"}},{"id":1133277,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-27T21:42:07.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":7.48,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-25-053093","document":"tm2516118-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465925053093/tm2516118-2_4seq1.xml","form_type":"4"}},{"id":1133276,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-27T21:42:07.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":16666,"source":{"system":"sec-edgar","filing":"0001104659-25-053093","document":"tm2516118-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465925053093/tm2516118-2_4seq1.xml","form_type":"4"}},{"id":1323984,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-21T01:30:54.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":1000000,"derivative":{"exercise_price":1.02,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000950170-24-139240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000095017024139240/ownership.xml","form_type":"4"}},{"id":1323983,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-12-21T01:30:54.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of compensatory Restricted Stock Units (\"RSUs\") granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":500000,"source":{"system":"sec-edgar","filing":"0000950170-24-139240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000095017024139240/ownership.xml","form_type":"4"}},{"id":1416937,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-09-05T01:13:28.000Z","date":"2024-09-01","kind":"exercise","planned":false,"acquired":false,"shares":11904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0000805928-24-000121","document":"wk-form4_1725498802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000121/wk-form4_1725498802.xml","form_type":"4"}},{"id":1416936,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T01:13:28.000Z","date":"2024-09-01","kind":"exercise","planned":false,"acquired":true,"shares":11904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that vested on September 1,  2024."}],"balance_after":29016,"source":{"system":"sec-edgar","filing":"0000805928-24-000121","document":"wk-form4_1725498802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000121/wk-form4_1725498802.xml","form_type":"4"}},{"id":1473026,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T00:27:27.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":3.27,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-24-073599","document":"tm2417704-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465924073599/tm2417704-7_4seq1.xml","form_type":"4"}},{"id":1473025,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T00:27:27.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\") granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":8333,"source":{"system":"sec-edgar","filing":"0001104659-24-073599","document":"tm2417704-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465924073599/tm2417704-7_4seq1.xml","form_type":"4"}},{"id":1485715,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to purchase)","published_at":"2024-06-10T22:20:59.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":18248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units."}],"balance_after":18248,"derivative":{"exercise_price":7.04,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":18248},"source":{"system":"sec-edgar","filing":"0000805928-24-000099","document":"wk-form4_1718058050.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000099/wk-form4_1718058050.xml","form_type":"4"}},{"id":1485714,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T22:20:59.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":10653,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."}],"balance_after":17112,"source":{"system":"sec-edgar","filing":"0000805928-24-000099","document":"wk-form4_1718058050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000099/wk-form4_1718058050.xml","form_type":"4"}},{"id":1489798,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:18:54.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders."}],"balance_after":890983,"source":{"system":"sec-edgar","filing":"0001867096-24-000106","document":"wk-form4_1717618723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709624000106/wk-form4_1717618723.xml","form_type":"4"}},{"id":1556151,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T21:43:04.000Z","date":"2024-03-15","kind":"other","planned":false,"acquired":true,"shares":89571,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Keveyis Sales 2023 Milestone achieved resulting in the settlement of the related Contingent Value Right (\"CVR\") in shares of Xeris Biopharma Holdings, Inc. (the \"Company\")'s Common Stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on October 5, 2021, the effective time of the Merger (as defined below), pursuant to the transaction agreement dated as of May 24, 2021 by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), where HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge, and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The number of shares of Common Stock for the CVR is equal to the product (A) $0.25 divided by the volume weighted average price for the Company's Common Stock as reported by\nNasdaq for the ten (10) Trading Days immediately prior to October 5, 2021 and (B) the number of CVRs held by the holder as reflected on the CVR Register."}],"balance_after":840983,"source":{"system":"sec-edgar","filing":"0001867096-24-000039","document":"wk-form4_1712007768.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709624000039/wk-form4_1712007768.xml","form_type":"4"}},{"id":1572234,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-18T21:32:20.000Z","date":"2024-03-18","kind":"exercise","planned":false,"acquired":false,"shares":215600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options to purchase shares of Xeris Biopharma Holdings Inc. common stock fully vested on October 5, 2021."}],"balance_after":0,"derivative":{"exercise_price":1.99,"expiration_date":"2029-11-14","underlying":"Common Stock","underlying_shares":215600},"source":{"system":"sec-edgar","filing":"0001867096-24-000036","document":"wk-form4_1710797522.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709624000036/wk-form4_1710797522.xml","form_type":"4"}},{"id":1572233,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-18T21:32:20.000Z","date":"2024-03-18","kind":"exercise","planned":false,"acquired":true,"shares":215600,"price":1.99,"value":429044.0,"ownership":{"direct":true},"balance_after":751412,"source":{"system":"sec-edgar","filing":"0001867096-24-000036","document":"wk-form4_1710797522.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709624000036/wk-form4_1710797522.xml","form_type":"4"}},{"id":1578568,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T22:14:17.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":8549,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date."}],"balance_after":8549,"derivative":{"exercise_price":11.44,"expiration_date":"2034-03-11","underlying":"Common Stock","underlying_shares":8549},"source":{"system":"sec-edgar","filing":"0001104659-24-034041","document":"tm248737-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465924034041/tm248737-5_4seq1.xml","form_type":"4"}},{"id":1578567,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T22:14:17.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled stock option was granted on June 28, 2021 and provided for vesting in twelve equal month installments beginning on the on the last day of each month over a period from June 2021 to May 2022."}],"balance_after":0,"derivative":{"exercise_price":49.92,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":2083},"source":{"system":"sec-edgar","filing":"0001104659-24-034041","document":"tm248737-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465924034041/tm248737-5_4seq1.xml","form_type":"4"}},{"id":1578566,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T22:14:17.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled stock option was granted on June 16, 2020 and provided for vesting in twelve equal monthly installments beginning on June 30, 2020 and ending on May 31, 2021."}],"balance_after":0,"derivative":{"exercise_price":21.24,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0001104659-24-034041","document":"tm248737-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465924034041/tm248737-5_4seq1.xml","form_type":"4"}},{"id":1578565,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T22:14:17.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The canceled stock option was granted on April 29, 2020 and provided for vesting in twelve equal monthly beginning on May 29, 2020 and ending on April 29, 2021."}],"balance_after":0,"derivative":{"exercise_price":21.72,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":2083},"source":{"system":"sec-edgar","filing":"0001104659-24-034041","document":"tm248737-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465924034041/tm248737-5_4seq1.xml","form_type":"4"}},{"id":1578564,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T22:14:17.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled stock option was granted on January 3, 2020 and provided for cliff vesting on June 3, 2021."}],"balance_after":0,"derivative":{"exercise_price":15.6,"expiration_date":"2030-01-03","underlying":"Common Stock","underlying_shares":2083},"source":{"system":"sec-edgar","filing":"0001104659-24-034041","document":"tm248737-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465924034041/tm248737-5_4seq1.xml","form_type":"4"}},{"id":1786362,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-09-07T10:29:32.000Z","date":"2023-09-01","kind":"grant","planned":false,"acquired":true,"shares":11904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting."}],"balance_after":11904,"derivative":{"underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0000805928-23-000114","document":"wf-form4_169408255914339.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000114/wf-form4_169408255914339.xml","form_type":"4"}},{"id":1786361,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2023-09-07T10:29:32.000Z","date":"2023-09-01","kind":"grant","planned":false,"acquired":true,"shares":20436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting."}],"balance_after":20436,"derivative":{"exercise_price":6.3,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":20436},"source":{"system":"sec-edgar","filing":"0000805928-23-000114","document":"wf-form4_169408255914339.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000114/wf-form4_169408255914339.xml","form_type":"4"}},{"id":1863747,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-07T20:59:34.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 7, 2024 or the date of the Company's next annual meeting of stockholders."}],"balance_after":535812,"source":{"system":"sec-edgar","filing":"0001867096-23-000099","document":"wk-form4_1686171564.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709623000099/wk-form4_1686171564.xml","form_type":"4"}},{"id":1868349,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T22:53:56.000Z","date":"2023-06-01","kind":"exercise","planned":false,"acquired":false,"shares":6459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6459},"source":{"system":"sec-edgar","filing":"0000805928-23-000066","document":"wf-form4_168600562557232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000066/wf-form4_168600562557232.xml","form_type":"4"}},{"id":1868348,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T22:53:56.000Z","date":"2023-06-01","kind":"exercise","planned":false,"acquired":true,"shares":6459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that vested on June 1, 2023."}],"balance_after":6459,"source":{"system":"sec-edgar","filing":"0000805928-23-000066","document":"wf-form4_168600562557232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000066/wf-form4_168600562557232.xml","form_type":"4"}},{"id":1891345,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-16T20:33:32.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2023 to April, 2024 and the last installment shall vest on the earlier of (i) the day before the 2024 Annual Meeting of Stockholders is held or (ii) May 31, 2024, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date."}],"balance_after":62500,"derivative":{"exercise_price":0.42,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001104659-23-061421","document":"tm2315836-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465923061421/tm2315836-5_4seq1.xml","form_type":"4"}},{"id":2079632,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-20T21:07:17.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 24, 2022 the Reporting Person filed a Form 4 reporting a stock option grant which incorrectly stated an exercise price of $1.11, a transaction date of June 22, 2022 and an expiration date of June 22, 2032. This amendment is being filed to reflect the corrected exercise price of $1.07, transaction date of May 12, 2022 and expiration date of May 12, 2032."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":62500,"derivative":{"exercise_price":1.07,"expiration_date":"2032-05-12","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001104659-22-128631","document":"tm2232937-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465922128631/tm2232937-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2022-06-24"}},{"id":2221937,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:11:05.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date."}],"balance_after":62500,"derivative":{"exercise_price":1.11,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001104659-22-074309","document":"tm2219034-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465922074309/tm2219034-6_4seq1.xml","form_type":"4"}},{"id":2237575,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:13:38.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":2.1,"exercise_date":"2022-06-08","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001867096-22-000090","document":"wf-form4_165480920373949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709622000090/wf-form4_165480920373949.xml","form_type":"4"}},{"id":2237574,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T21:13:38.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders."}],"balance_after":493312,"source":{"system":"sec-edgar","filing":"0001867096-22-000090","document":"wf-form4_165480920373949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000186709622000090/wf-form4_165480920373949.xml","form_type":"4"}},{"id":2246236,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-03T20:14:05.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":6459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units."}],"balance_after":6459,"derivative":{"underlying":"Common Stock","underlying_shares":6459},"source":{"system":"sec-edgar","filing":"0000805928-22-000067","document":"wf-form4_165428722800361.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000067/wf-form4_165428722800361.xml","form_type":"4"}},{"id":2246235,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to purchase)","published_at":"2022-06-03T20:14:05.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":11811,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units."}],"balance_after":11811,"derivative":{"exercise_price":9.29,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":11811},"source":{"system":"sec-edgar","filing":"0000805928-22-000067","document":"wf-form4_165428722800361.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000067/wf-form4_165428722800361.xml","form_type":"4"}},{"id":2545404,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-08T22:29:41.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":19650,"price":2.37,"value":46570.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of these options shall vest in equal annual installments until the third anniversary of the date of grant."}],"balance_after":19650,"derivative":{"exercise_price":2.37,"expiration_date":"2031-10-05","underlying":"Common Stock","underlying_shares":19650},"source":{"system":"sec-edgar","filing":"0000899243-21-039749","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039749/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-05"}},{"id":2545403,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-08T22:29:41.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":68600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":68600,"derivative":{"exercise_price":2.43,"expiration_date":"2030-04-08","underlying":"Common Stock","underlying_shares":68600},"source":{"system":"sec-edgar","filing":"0000899243-21-039749","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039749/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-05"}},{"id":2545402,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-08T22:29:41.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":215600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":215600,"derivative":{"exercise_price":1.99,"expiration_date":"2029-11-14","underlying":"Common Stock","underlying_shares":215600},"source":{"system":"sec-edgar","filing":"0000899243-21-039749","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039749/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-05"}},{"id":2545401,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-08T22:29:41.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":31360,"derivative":{"exercise_price":9.89,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0000899243-21-039749","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039749/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-05"}},{"id":2545400,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-08T22:29:41.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":31360,"derivative":{"exercise_price":5.62,"expiration_date":"2027-05-11","underlying":"Common Stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0000899243-21-039749","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039749/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-05"}},{"id":2545399,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-08T22:29:41.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":31360,"derivative":{"exercise_price":7.02,"expiration_date":"2026-05-12","underlying":"Common Stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0000899243-21-039749","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039749/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-05"}},{"id":2545398,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-08T22:29:41.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":10367,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":10367,"derivative":{"exercise_price":22.39,"expiration_date":"2025-10-16","underlying":"Common Stock","underlying_shares":10367},"source":{"system":"sec-edgar","filing":"0000899243-21-039749","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039749/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-05"}},{"id":2545397,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-08T22:29:41.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":478312,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\"). At the effective time of the Merger (the \"Merger Effective Time\"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\"). At the effective time of the Merger (the \"Merger Effective Time\"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis."}],"balance_after":478312,"source":{"system":"sec-edgar","filing":"0000899243-21-039749","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039749/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-05"}},{"id":2547066,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-06T23:42:17.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":495724,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":495724},"source":{"system":"sec-edgar","filing":"0001179110-21-009282","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911021009282/edgar.xml","form_type":"4"}},{"id":2547065,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-10-06T23:42:17.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":610092,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. (\"HoldCo\") pursuant to the Transaction Agreement (the \"Agreement\"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a \"CVR\") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. (\"HoldCo\") pursuant to the Transaction Agreement (the \"Agreement\"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a \"CVR\") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-21-009282","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911021009282/edgar.xml","form_type":"4"}},{"id":2548583,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:52:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":68600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":68600,"derivative":{"exercise_price":2.43,"expiration_date":"2030-04-08","underlying":"Common Stock","underlying_shares":68600},"source":{"system":"sec-edgar","filing":"0000899243-21-039341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039341/doc4.xml","form_type":"4"}},{"id":2548582,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:52:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":215600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":215600,"derivative":{"exercise_price":1.99,"expiration_date":"2029-11-14","underlying":"Common Stock","underlying_shares":215600},"source":{"system":"sec-edgar","filing":"0000899243-21-039341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039341/doc4.xml","form_type":"4"}},{"id":2548581,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:52:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":31360,"derivative":{"exercise_price":9.89,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0000899243-21-039341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039341/doc4.xml","form_type":"4"}},{"id":2548580,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:52:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":31360,"derivative":{"exercise_price":5.62,"expiration_date":"2027-05-11","underlying":"Common Stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0000899243-21-039341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039341/doc4.xml","form_type":"4"}},{"id":2548579,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:52:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":31360,"derivative":{"exercise_price":7.02,"expiration_date":"2026-05-12","underlying":"Common Stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0000899243-21-039341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039341/doc4.xml","form_type":"4"}},{"id":2548578,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:52:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":10367,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":10367,"derivative":{"exercise_price":22.39,"expiration_date":"2025-10-16","underlying":"Common Stock","underlying_shares":10367},"source":{"system":"sec-edgar","filing":"0000899243-21-039341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039341/doc4.xml","form_type":"4"}},{"id":2548577,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T23:52:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":478312,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\"). At the effective time of the Merger (the \"Merger Effective Time\"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\"). At the effective time of the Merger (the \"Merger Effective Time\"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis."}],"balance_after":478312,"source":{"system":"sec-edgar","filing":"0000899243-21-039341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924321039341/doc4.xml","form_type":"4"}},{"id":2548576,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-10-05T23:24:45.000Z","date":"2021-10-01","kind":"tax_withholding","acquired":false,"shares":334868,"price":2.06,"value":689828.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":610092,"source":{"system":"sec-edgar","filing":"0001179110-21-009224","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911021009224/edgar.xml","form_type":"4"}},{"id":2628759,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-07-21T20:10:27.000Z","date":"2021-07-19","kind":"grant","acquired":true,"shares":27638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in three equal installments on the annual anniversary of the grant date with the first vesting date occurring on July 19, 2022."}],"balance_after":27638,"derivative":{"exercise_price":19.44,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":27638},"source":{"system":"sec-edgar","filing":"0000899243-21-029207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000089924321029207/doc4.xml","form_type":"4"}},{"id":2639261,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-07-07T21:01:44.000Z","date":"2021-07-02","kind":"tax_withholding","acquired":false,"shares":50867,"price":3.08,"value":156670.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":944960,"source":{"system":"sec-edgar","filing":"0001179110-21-007439","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911021007439/edgar.xml","form_type":"4"}},{"id":2649683,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-30T18:00:08.000Z","date":"2021-06-28","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":4.16,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-087403","document":"tm2121071-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465921087403/tm2121071-5_4seq1.xml","form_type":"4"}},{"id":2752024,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-04-09T21:13:35.000Z","date":"2021-04-08","kind":"tax_withholding","acquired":false,"shares":17325,"price":2.68,"value":46431.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":995827,"source":{"system":"sec-edgar","filing":"0001179110-21-004361","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911021004361/edgar.xml","form_type":"4"}},{"id":2912104,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-01-08T13:33:24.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":491000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units, which vest in full on January 7, 2023, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":1013152,"source":{"system":"sec-edgar","filing":"0001179110-21-000424","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911021000424/edgar.xml","form_type":"4"}},{"id":3087393,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-07-07T12:11:57.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). One-half of the RSUs will vest on July 2, 2021 with the remaining one-half of the RSUs vesting on July 2, 2022, provided the Reporting Person is employed by, or providing services to, the Issuer on each vesting date. Each RSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":522152,"source":{"system":"sec-edgar","filing":"0001179110-20-008088","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911020008088/edgar.xml","form_type":"4"}},{"id":3091481,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T20:29:19.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":54991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Merger, these options were accelerated and canceled without payment."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":54991},"source":{"system":"sec-edgar","filing":"0001209191-20-040321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000120919120040321/doc4.xml","form_type":"4"}},{"id":3091480,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T20:29:19.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":11377,"price":0.06,"value":682.62,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."}],"balance_after":0,"derivative":{"exercise_price":17.94,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":11377},"source":{"system":"sec-edgar","filing":"0001209191-20-040321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000120919120040321/doc4.xml","form_type":"4"}},{"id":3091479,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-07-02T20:29:19.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":7281,"price":18,"value":131058.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"At the Effective Time, each restricted stock unit (\"RSU\") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-040321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000120919120040321/doc4.xml","form_type":"4"}},{"id":3091478,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-02T20:29:19.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":13194,"price":18,"value":237492.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the \"Issuer\"), Alexion\nPharmaceuticals, Inc. (\"Alexion\") and Odyssey Merger Sub Inc. (\"Merger Sub\") (the \"Merger Agreement\"), on July 2, 2020, Merger Sub merged with and\ninto the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the \"Merger\"). At the\neffective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $18.00 per share in cash, without interest and\nsubject to any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-040321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000120919120040321/doc4.xml","form_type":"4"}},{"id":3105355,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-18T21:31:49.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":27602,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on June 30, 2020 and ending on May 31, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":27602,"derivative":{"exercise_price":1.77,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":27602},"source":{"system":"sec-edgar","filing":"0000904454-20-000404","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000090445420000404/edgar.xml","form_type":"4"}},{"id":3110425,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-15T22:59:45.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":11377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date."}],"balance_after":11377,"derivative":{"exercise_price":17.94,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":11377},"source":{"system":"sec-edgar","filing":"0001209191-20-036767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000120919120036767/doc4.xml","form_type":"4"}},{"id":3110424,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-15T22:59:45.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":7281,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\") in consideration of services rendered. The RSUs fully vest on March 1, 2021, subject to the Reporting Person's Continuous Services (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date."}],"balance_after":20475,"source":{"system":"sec-edgar","filing":"0001209191-20-036767","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000120919120036767/doc4.xml","form_type":"4"}},{"id":3145269,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Ordinary Shares","published_at":"2020-05-18T20:51:19.000Z","date":"2020-05-15","kind":"tax_withholding","acquired":false,"shares":15348,"price":2.86,"value":43895.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":207152,"source":{"system":"sec-edgar","filing":"0001179110-20-006239","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911020006239/edgar.xml","form_type":"4"}},{"id":3167320,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-29T22:19:21.000Z","date":"2020-04-29","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on May 29, 2020 and ending on April 29, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.81,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-20-053602","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000110465920053602/a4.xml","form_type":"4"}},{"id":3178488,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-04-10T12:07:13.000Z","date":"2020-04-08","kind":"grant","acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in sixteen equal quarterly installments beginning May 8, 2020, provided that the Reporting Person continues to serve as Executive Chairman and as a member of the board of directors of the Issuer through each such vesting date."}],"balance_after":87500,"derivative":{"exercise_price":1.9,"expiration_date":"2030-04-08","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001179110-20-004824","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911020004824/edgar.xml","form_type":"4"}},{"id":3178487,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Ordinary Shares","published_at":"2020-04-10T12:07:13.000Z","date":"2020-04-08","kind":"grant","acquired":true,"shares":182500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units, which vest in three equal annual installments on each of the first three anniversaries of the grant date, provided that the Reporting Person continues to serve as Executive Chairman and as a member of the board of directors of the Issuer through each such vesting date. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":222500,"source":{"system":"sec-edgar","filing":"0001179110-20-004824","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911020004824/edgar.xml","form_type":"4"}},{"id":3368053,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-18T22:33:04.000Z","date":"2019-11-14","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted in connection with the Reporting Person's appointment as executive chairman of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in sixteen equal quarterly installments beginning February 14, 2020, provided the Reporting Person is employed by or serving as a director of the Issuer on each vesting date."}],"balance_after":275000,"derivative":{"exercise_price":1.56,"expiration_date":"2029-11-14","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001179110-19-011796","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911019011796/edgar.xml","form_type":"4"}},{"id":3471145,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Melinta Common Stock","published_at":"2019-07-02T21:09:33.000Z","date":"2019-06-27","kind":"sale","acquired":false,"shares":13000,"price":5.5724,"value":72441.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares necessary to cover tax withholding obligations in connection with the vesting of the Reporting Person's RSUs."}],"balance_after":37400,"source":{"system":"sec-edgar","filing":"0001461993-19-000037","document":"wf-form4_156211615828793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461993/000146199319000037/wf-form4_156211615828793.xml","form_type":"4"}},{"id":3478023,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Melinta Restricted Stock Units","published_at":"2019-06-26T16:06:57.000Z","date":"2019-05-22","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date."}],"balance_after":350000,"derivative":{"exercise_price":0,"underlying":"Melinta Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001461993-19-000035","document":"wf-form4_156157960106867.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1461993/000146199319000035/wf-form4_156157960106867.xml","form_type":"4"}},{"id":3478022,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Melinta Common Stock","published_at":"2019-06-26T16:06:57.000Z","date":"2019-05-22","kind":"exercise","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50400,"source":{"system":"sec-edgar","filing":"0001461993-19-000035","document":"wf-form4_156157960106867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461993/000146199319000035/wf-form4_156157960106867.xml","form_type":"4"}},{"id":3487608,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T21:26:44.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":6991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date."}],"balance_after":6991,"derivative":{"exercise_price":26.09,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":6991},"source":{"system":"sec-edgar","filing":"0001209191-19-037457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000120919119037457/doc4.xml","form_type":"4"}},{"id":3487607,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T21:26:44.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":4194,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\") in consideration of services rendered. The RSUs fully vest on March 1, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date."}],"balance_after":13194,"source":{"system":"sec-edgar","filing":"0001209191-19-037457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000120919119037457/doc4.xml","form_type":"4"}},{"id":3523701,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-16T20:12:56.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units, which vest in full on May 15, 2020, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date.  Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001179110-19-006149","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000117911019006149/edgar.xml","form_type":"4"}},{"id":3632013,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-26T21:47:56.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date."}],"balance_after":400000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000899243-19-004939","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461993/000089924319004939/doc4.xml","form_type":"4"}},{"id":3781219,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Restricted Stock Units","published_at":"2018-10-29T17:30:04.000Z","date":"2018-10-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award vests in full and will be settled on October 18, 2019, subject to the Reporting Person continuing to provide services in any capacity (including, but not limited to, service as a member of the Board of Directors)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The award vests in full and will be settled on October 18, 2019, subject to the Reporting Person continuing to provide services in any capacity (including, but not limited to, service as a member of the Board of Directors)."}],"balance_after":50000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-027585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1461993/000089924318027585/doc4.xml","form_type":"4"}},{"id":3781218,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-10-29T17:30:04.000Z","date":"2018-10-26","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award vests in equal monthly installments over a period of 12 months from October 18, 2018, subject to the Reporting Person continuing to provide services in any capacity (including, but not limited to, service as a member of the Board of Directors)."}],"balance_after":150000,"derivative":{"exercise_price":2.8,"expiration_date":"2028-10-26","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-18-027585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461993/000089924318027585/doc4.xml","form_type":"4"}},{"id":3888452,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":13228,"kind":"person","name":"JOHNSON JOHN","position":1,"cik":"0001410781","reported_name":"JOHNSON JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T20:41:06.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018."}],"balance_after":25000,"derivative":{"exercise_price":2.97,"expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-017186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410781/000089924318017186/doc4.xml","form_type":"4"}}],"next_cursor":"2018-06-19T20:41:06.000000Z,3888452"}